---
title: "Fudan-Zhangjiang Deploys RMB110 Million in Low-Risk Structured Deposits"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271770137.md"
description: "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. has invested RMB110 million in low-risk structured deposits from China Merchants Bank. The 83-day term products offer an expected annual return of 1.00%–1.65% linked to gold. This investment is classified as a cautious-risk transaction under Hong Kong listing rules, requiring reporting but not shareholder approval. The company aims to enhance returns on surplus cash while maintaining its risk profile and capital structure. Fudan-Zhangjiang is a biopharmaceutical firm focused on research and development in the healthcare sector, with a market cap of HK$965 million."
datetime: "2026-01-07T09:39:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271770137.md)
  - [en](https://longbridge.com/en/news/271770137.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271770137.md)
---

# Fudan-Zhangjiang Deploys RMB110 Million in Low-Risk Structured Deposits

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

An update from Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( (HK:1349) ) is now available.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical and its wholly owned subsidiary Taizhou Fudan-Zhangjiang have subscribed to principal-guaranteed structured deposit products offered by China Merchants Bank, deploying a total of RMB110 million of idle operating funds. The products, which have an 83-day term and offer an expected annualised return of 1.00%–1.65% linked to gold, are classified as cautious-risk investments and constitute discloseable transactions under Hong Kong listing rules, triggering reporting and announcement requirements but not shareholder approval, thereby enabling the company to enhance returns on surplus cash without materially altering its risk profile or capital structure.

**More about Shanghai Fudan Zhangjiang Bio Pharmaceutical Co**

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. is a Hong Kong-listed biopharmaceutical company engaged in the research, development and commercialisation of pharmaceutical products, operating within the broader healthcare and life sciences industry. The group focuses on leveraging its financial resources from daily operations to support its business while managing liquidity and investment returns through low-risk financial instruments.

**Average Trading Volume:** 1,941,775

**Current Market Cap:** HK$965M

### Related Stocks

- [01349.HK](https://longbridge.com/en/quote/01349.HK.md)
- [688505.CN](https://longbridge.com/en/quote/688505.CN.md)

## Related News & Research

- [Hong Kong minister touts gold as ‘bridge between conventional and new finance’](https://longbridge.com/en/news/287071587.md)
- [Gold mining ETFs trail bullion despite strong miner earnings](https://longbridge.com/en/news/286954910.md)
- [Gold Is Quietly Becoming The Most Ignored Trade Again](https://longbridge.com/en/news/286780387.md)
- [Gold fell below $4,500. How long will this correction last?](https://longbridge.com/en/news/287066305.md)
- [Goldman lifts central bank gold buying estimates, keeps $5,400 target](https://longbridge.com/en/news/287106969.md)